COVID-19 Vaccine Of Moderna Shows Good Efficacy In Clinical Trials by Pooja Shete on January 1, 2021 at 7:27 PM
Data from the much-anticipated COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc, provides evidence that the vaccine can prevent symptomatic infection. The study will continue for two years more.
The trial which evaluated more than 30,000 participants randomized to receive the vaccine or a placebo showed that 11 participants in the vaccine group developed symptomatic COVID-19 when compared to 185 participants who received the placebo. The vaccine showed an efficacy of 94.1 percent in preventing symptomatic COVID-19. Only in one participant a severe case of COVID-19 was seen.